Teduglutide - Takeda
Alternative Names: ALX-0600; Gattex; Revestive; TAK 633; Teduglutide - ShireLatest Information Update: 27 May 2024
At a glance
- Originator Toronto General Hospital; University of Toronto
- Developer Shire; Takeda; Takeda Pharmaceuticals International GmbH
- Class Anti-inflammatories; Peptides
- Mechanism of Action Glucagon-like peptide 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Crohn's disease
Highest Development Phases
- Marketed Short bowel syndrome
- Suspended Crohn's disease
- No development reported Mucositis
Most Recent Events
- 29 Feb 2024 Registered for Short bowel syndrome in China (SC), before February 2024 (Takeda pipeline, May 2024)
- 27 Sep 2023 Takeda completes a phase III trial in Short bowel syndrome (In infants, In children, In adolescents, In adults, In the elderly) in Japan (SC) (NCT05027308)
- 01 Jun 2022 The National Institute for Health and Care Excellence (NICE) recommends teduglutide, once daily subcutaneous injection, as an option for people living with Short bowel syndrome (SBS) (In infants, In children, In adolescents, In adults, In the elderly) in United Kingdom